## Annual report   March 2024 

Annual educatonal meetng held on October 5[th] ,2023 

Mallinckrodt Sponsored Session 10:00 - 10:40 To improve overall survival in acute GvHD by applying ECP Dr. Melhem M. Solh, Northside Hospital, Atlanta, Georgia 

Sanofi Sponsored Session 10:40 - 11:20: The dual role of ROCK2 inhibitors and ECP in treating GvHD Dr Corey Cutler, Dana-Farber Cancer Institute, Boston, Massachusetts 11:20 - 11:40 

11.40 - 13.00 Nurse-led Symposium: Vascular access, Vascular Issues + Audit Ms Anne McDermott, 13:00 - 14:00 Lunch and Poster viewing 

14:00 - 14:45 UKPS Business meeting 

14:45 - 15:30 E-CLAD Trial: Update and progress Professor Andrew Fisher, Newcastle University 15:30 - 15:45 Afternoon coffee break 15:45 - 16:15 

E-CLAD: Immunology update Mr Steven Bolton, Newcastle University 16:15 - 16:45 

Investigating Extracellular Vesicles in ECP Response in Patients with GvHD Dr Rachel Crossland, Newcastle University 16:45 - 17:00 Summary & Close 

## Research Grants: 

‘Mechanisms of action of ECP therapy for GvHD, focusing on the role of EV-derived microRNAs”, which aims to further understanding the molecular mechanisms of ECP action, including EV microRNAs, as well as identify biomarkers for using ECP as first line or pre-emptive GvHD therapy.’ 

Dr Rachel Crossland newcastle University 




## Statement of accounts for the UKPS for Jan31 2023 to Jan 2024 presented to Board 

## **Charity registration number: 1178321** 

Jan 2023   Balance: £93,968 

Educatonal events: 

UKPS 2023 : £4,120 (Friends House) 

Research Grant Jan 2024 : New castle Uniersity £14,691.14 

Mallinckr0dt Ltd. : £20,000 ( paid in as meeting support) 

Current balance Sep 2019 : £102,597.26 


Dr Arun Alfred 1/3/24 Treasurer UKPS